Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of LYL797 in ROR1+ Solid Tumors
NCT05274451Phase 1Terminated
- Sponsor
- Lyell Immunopharma
- Start
- Mar 2022
- Primary completion
- Nov 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LYL797 in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), ovarian cancer and 1 more, sponsored by Lyell Immunopharma. Primary endpoints: Incidence of Dose-Limiting Toxicities up to 28 days, Incidence of Treatment-Emergent Adverse Events up to 2 years and 2 more. Started Mar 2022; status: terminated.
02
Drugs
LYL797
03
Conditions
triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT05274451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274451.